Evidence map›Paper›PMID 33169829›Full record

ArticleBiotechnology and bioengineering2021

In situ detection of protein interactions for recombinant therapeutic enzymes.

Mojtaba Samoudi, Chih-Chung Kuo, Caressa M Robinson, Km Shams-Ud-Doha, Song-Min Schinn, Stefan Kol, Linus Weiss, Sara Petersen Bjorn, Bjorn G Voldborg, Alexandre Rosa Campos and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Mojtaba SamoudiDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Chih-Chung KuoNovo Nordisk Foundation Center for Biosustainability, UC San Diego, La Jolla, California, USA.
Caressa M RobinsonNovo Nordisk Foundation Center for Biosustainability, UC San Diego, La Jolla, California, USA.
Km Shams-Ud-DohaProteomics Core, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Song-Min SchinnDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Stefan KolNovo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Linus WeissDepartment of Biochemistry, Eberhard Karls University of Tübingen, Tübingen, Germany.
Sara Petersen BjornNovo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Bjorn G VoldborgNovo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Alexandre Rosa CamposProteomics Core, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Nathan E LewisDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0001-7700-3654
Novo Nordisk Foundation · DKSanford Burnham Prebys Medical Discovery Institute · USUniversity of Tübingen · DE

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Unraveling the mammalian secretory pathway through systems biology and algorithm developmentR35GM119850 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEWIS, NATHAN ENOCH · 2016 to 2025
$4.3M
NCI NIH HHS P30 CA030199NIGMS NIH HHS R35 GM119850NINDS NIH HHS P30 NS047101Novo Nordisk Fonden NNF10CC1016517
6 · The paper itself

Abstract

Despite their therapeutic potential, many protein drugs remain inaccessible to patients since they are difficult to secrete. Each recombinant protein has unique physicochemical properties and requires different machinery for proper folding, assembly, and posttranslational modifications (PTMs). Here we aimed to identify the machinery supporting recombinant protein secretion by measuring the protein-protein interaction (PPI) networks of four different recombinant proteins (SERPINA1, SERPINC1, SERPING1, and SeAP) with various PTMs and structural motifs using the proximity-dependent biotin identification (BioID) method. We identified PPIs associated with specific features of the secreted proteins using a Bayesian statistical model and found proteins involved in protein folding, disulfide bond formation, and N-glycosylation were positively correlated with the corresponding features of the four model proteins. Among others, oxidative folding enzymes showed the strongest association with disulfide bond formation, supporting their critical roles in proper folding and maintaining the ER stability. Knockdown of disulfide-isomerase PDIA4, a measured interactor with significance for SERPINC1 but not SERPINA1, led to the decreased secretion of SERPINC1, which relies on its extensive disulfide bonds, compared to SERPINA1, which has no disulfide bonds. Proximity-dependent labeling successfully identified the transient interactions supporting synthesis of secreted recombinant proteins and refined our understanding of key molecular mechanisms of the secretory pathway during recombinant protein production.

Indexed as

Protein Interaction MapsProtein Processing, Post-TranslationalGlycosylationHEK293 CellsHumansProtein FoldingProtein TransportRecombinant ProteinsRecombinant ProteinsBioIDcell engineeringdisulfide bondsecretory pathwaytherapeutic proteins

Identifiers

PMID33169829
PMCPMC7855575
OpenAlexW3105285685

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.